PubRank

Benedetto Vitiello

Author PubWeight™ 259.12‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004 15.34
2 Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006 11.25
3 Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 2006 10.19
4 Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry 2006 10.00
5 Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 2006 9.98
6 Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006 9.85
7 Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002 9.35
8 The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009 6.71
9 Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008 4.91
10 The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007 3.78
11 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007 3.33
12 Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008 3.30
13 Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009 3.17
14 Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006 2.95
15 Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005 2.94
16 Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 2009 2.65
17 Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry 2011 2.55
18 Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006 2.52
19 The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up. J Am Acad Child Adolesc Psychiatry 2013 2.48
20 Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006 2.45
21 Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry 2010 2.32
22 Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry 2013 2.30
23 Stimulant medication use in children: a 12-year perspective. Am J Psychiatry 2012 2.27
24 Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006 2.26
25 The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry 2009 2.13
26 Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007 2.03
27 Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 2003 2.02
28 Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning. J Abnorm Child Psychol 2007 1.98
29 Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 2007 1.98
30 Cost-effectiveness of treatments for adolescent depression: results from TADS. Am J Psychiatry 2008 1.86
31 Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry 2009 1.85
32 The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2006 1.82
33 Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2007 1.78
34 Medication use in US youth with mental disorders. JAMA Pediatr 2013 1.75
35 Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry 2006 1.71
36 Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 2010 1.69
37 Validity of the autism diagnostic interview-revised. Am J Ment Retard 2006 1.66
38 Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry 2012 1.62
39 Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2006 1.61
40 Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009 1.55
41 AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2004 1.53
42 Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry 2009 1.51
43 Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 2007 1.48
44 Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol 2003 1.46
45 Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord 2008 1.46
46 Observed classroom behavior of children with ADHD: relationship to gender and comorbidity. J Abnorm Child Psychol 2002 1.45
47 Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003 1.42
48 Peer-assessed outcomes in the multimodal treatment study of children with attention deficit hyperactivity disorder. J Clin Child Adolesc Psychol 2005 1.41
49 Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Am Acad Child Adolesc Psychiatry 2007 1.36
50 Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2004 1.34
51 Assessing medication effects in the MTA study using neuropsychological outcomes. J Child Psychol Psychiatry 2006 1.34
52 Parent-reported homework problems in the MTA study: evidence for sustained improvement with behavioral treatment. J Clin Child Adolesc Psychol 2010 1.31
53 Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord 2008 1.27
54 Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry 2005 1.26
55 Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 2005 1.24
56 Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007 1.24
57 The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 2009 1.24
58 The transition to middle school is associated with changes in the developmental trajectory of ADHD symptomatology in young adolescents with ADHD. J Clin Child Adolesc Psychol 2008 1.24
59 Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry 2002 1.23
60 Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2009 1.21
61 Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2006 1.18
62 Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. J Atten Disord 2008 1.18
63 Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 2004 1.16
64 Acute time to response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006 1.16
65 Substance use and the treatment of resistant depression in adolescents. J Am Acad Child Adolesc Psychiatry 2009 1.16
66 Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 2010 1.15
67 AACAP 2001 research forum: challenges and recommendations regarding recruitment and retention of participants in research investigations. J Am Acad Child Adolesc Psychiatry 2004 1.15
68 Sources of site differences in the efficacy of a multisite clinical trial: the Treatment of SSRI-Resistant Depression in Adolescents. J Consult Clin Psychol 2009 1.15
69 Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003 1.13
70 A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 2012 1.13
71 Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2007 1.09
72 Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry 2007 1.08
73 Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry 2005 1.05
74 Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems. J Am Acad Child Adolesc Psychiatry 2011 1.05
75 Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. J Abnorm Child Psychol 2004 1.03
76 Exploring the manifestations of anxiety in children with autism spectrum disorders. J Autism Dev Disord 2013 1.02
77 Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidate. Proc Natl Acad Sci U S A 2011 1.02
78 Parent versus teacher ratings of attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007 1.01
79 Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007 1.00
80 A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2007 0.99
81 Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord 2013 0.98
82 Factor structure of parent- and teacher-rated attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007 0.97
83 The role of anxiety symptoms in school performance in a community sample of children and adolescents. BMC Public Health 2007 0.97
84 Selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable? J Child Adolesc Psychopharmacol 2006 0.97
85 Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder. J Consult Clin Psychol 2006 0.96
86 Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol 2011 0.96
87 Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J Autism Dev Disord 2008 0.96
88 Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry 2009 0.96
89 Clinical messages from the Treatment for Adolescents With Depression Study (TADS). Am J Psychiatry 2009 0.96
90 Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010 0.94
91 Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems. Child Adolesc Psychiatr Clin N Am 2014 0.94
92 A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006 0.94
93 Obsessive-compulsive traits in children and adolescents with Asperger syndrome. Eur Child Adolesc Psychiatry 2009 0.94
94 Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 2008 0.94
95 Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry 2011 0.93
96 Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescent Study (TORDIA). J Am Acad Child Adolesc Psychiatry 2011 0.93
97 Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy. Arch Gen Psychiatry 2008 0.93
98 Factors associated with recruitment and screening in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2007 0.93
99 Safeguarding children's rights in psychopharmacological research: ethical and legal issues. Curr Pharm Des 2010 0.92
100 Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. Am J Psychiatry 2009 0.92
101 National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge. J Atten Disord 2004 0.92
102 Antidepressant prescribing practices for the treatment of children and adolescents. J Child Adolesc Psychopharmacol 2008 0.92
103 Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry 2003 0.91
104 Assessing patient beliefs in a clinical trial of Hypericum perforatum in major depression. Depress Anxiety 2004 0.90
105 Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007 0.90
106 Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. J Child Adolesc Psychopharmacol 2002 0.90
107 Economic evaluation of strategies to reduce sudden cardiac death in young athletes. Pediatrics 2012 0.89
108 Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007 0.89
109 Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study. J Affect Disord 2012 0.89
110 Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study. J Intellect Dev Disabil 2006 0.89
111 Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. Psychopharmacology (Berl) 2006 0.88
112 Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study. J Child Adolesc Psychopharmacol 2009 0.87
113 Developmental disabilities modification of the Children's Global Assessment Scale. Biol Psychiatry 2007 0.86
114 Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol 2008 0.86
115 Comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al. Cancer Lett 2005 0.85
116 Peer-reviewed, high quality, worldwide information on all topics relevant to child and adolescent mental health. Child Adolesc Psychiatry Ment Health 2007 0.85
117 Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and government. J Am Acad Child Adolesc Psychiatry 2006 0.84
118 Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs 2011 0.84
119 Service use and costs of care for depressed adolescents: who uses and who pays? J Clin Child Adolesc Psychol 2009 0.83
120 Neurocognition in early-onset schizophrenia and schizoaffective disorders. J Am Acad Child Adolesc Psychiatry 2010 0.83
121 Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. J Child Adolesc Psychopharmacol 2010 0.83
122 Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. J Neurovirol 2006 0.81
123 Unmet need for services and interventions among adolescents with mental disorders. Am J Psychiatry 2007 0.81
124 Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003 0.81
125 Use of atypical antipsychotics in children: balancing safety and effectiveness. Am Fam Physician 2010 0.81
126 Prevention and treatment of the psychological consequences of trauma in children and adolescents. Epidemiol Psichiatr Soc 2004 0.80
127 Children's hospitalizations with a mood disorder diagnosis in general hospitals in the united states 2000-2006. Child Adolesc Psychiatry Ment Health 2011 0.80
128 Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. J Child Adolesc Psychopharmacol 2012 0.80
129 Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. J Child Adolesc Psychopharmacol 2011 0.80
130 Datapoints: trends in combined pharmacotherapy with stimulants for children. Psychiatr Serv 2002 0.79
131 Stimulant treatment of ADHD and risk of sudden death in children. Am J Psychiatry 2009 0.79
132 Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders. J Dev Phys Disabil 2013 0.79
133 Effects of source of DNA on genotyping success rates and allele percentages in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007 0.79
134 Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study. Curr Psychiatry Rep 2005 0.79
135 Selecting an antidepressant for the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006 0.78
136 Prevalence of psychiatric symptoms in children and adolescents one year after the 2009 L'Aquila earthquake. BMC Psychiatry 2014 0.78
137 Open-label amantadine in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007 0.77
138 Emergency/Adjunct services and attrition prevention for randomized clinical trials in children: the MTA manual-based solution. J Am Acad Child Adolesc Psychiatry 2002 0.77
139 The genetic toxicity of methylphenidate: a review of the current literature. J Appl Toxicol 2012 0.76
140 Approaches to multisite clinical trials: the National Institute of Mental Health perspective. Schizophr Bull 2003 0.76
141 Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders. Biol Psychiatry 2002 0.76
142 The rapidly expanding field of autism research. Biol Psychiatry 2007 0.75
143 Child and Adolescent Psychiatry and Mental Health--development of a new open-access journal. Child Adolesc Psychiatry Ment Health 2008 0.75
144 Improving decision making in the treatment of ADHD. Am J Psychiatry 2008 0.75
145 Response to commentary on the multimodal treatment study of ADHD (MTA): mining the meaning of the MTA. J Abnorm Child Psychol 2002 0.75
146 Truly independent research? Treatment for Adolescents with Depression Study (TADS). BMJ 2008 0.75
147 The importance of the discourse on the method. Child Adolesc Psychiatry Ment Health 2010 0.75
148 Dr. Vitiello et al. reply. J Am Acad Child Adolesc Psychiatry 2013 0.75
149 Correction. J Clin Psychiatry 2019 0.75
150 Beware of over-interpreting negative trials. J Autism Dev Disord 2008 0.75
151 Selective serotonin reuptake inhibitors (SSRIs) in children and adolescents. J Child Adolesc Psychopharmacol 2006 0.75
152 How effective are the current treatments for children diagnosed with manic/mixed bipolar disorder? CNS Drugs 2013 0.75
153 Introduction: issues and viewpoints in pediatric psychopharmacology. Int Rev Psychiatry 2008 0.75
154 The development of targeted neurobiological therapies in child and adolescent psychiatry. J Am Acad Child Adolesc Psychiatry 2013 0.75